| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3282000 | Clinical Gastroenterology and Hepatology | 2014 | 7 Pages |
Abstract
Trough levels of adalimumab are significantly higher in IBD patients who are in clinical remission and in those with mucosal healing. Detection of antibodies against adalimumab predicts a lack of mucosal healing.
Keywords
AAATNFLHRCDAIAdalimumabAUROCIBDROCCrohn’s diseaseInflammatory bowel diseaseCrohn's Disease Activity IndexMucosal healingPrognostic factortumor necrosis factorarea under the receiver-operating characteristic curveOutcomeLikelihood ratioADAResponse to TherapyC-reactive proteinCRPUlcerative colitisreceiver-operating characteristic
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Xavier Roblin, Hubert Marotte, Melanie Rinaudo, Emilie Del Tedesco, Amelie Moreau, Jean Marc Phelip, Christian Genin, Laurent Peyrin-Biroulet, Stephane Paul,